Matthew Reaney

Good scientific principles and practices are essential for maintaining quality data that patients can benefit from.

Measuring clinically relevant response requires routine and regular collection of outcomes data.

Combining PRO data with clinical feasibility data can make a difference in diabetes care.

Type 2 diabetes mellitus is one of the Western world’s most common chronic conditions, with global prevalence increasing rapidly.

Trulicity® (dulaglutide), approved by the EMA in November 2014 for the treatment of Type 2 diabetes in adults, is the first diabetes drug to have a Patient Reported Outcome.